About Inositec
Inositec is a Healthcare company based in Zurich (Switzerland) founded in 2015, and was acquired by Vifor Pharma Benelux in November 2021. Therapeutics for soft tissue calcification disorders are developed. Inositec has raised $1.42 million across 3 funding rounds from investors including Zurcher Kantonalbank, CSL Vifor and VIP Partners. The company was acqui-hired. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Bacterial.
Company details
Inositec was founded in 2015 in Zurich, Switzerland, with operations centered in the biotechnology sector. Therapeutics addressing soft tissue calcification disorders are developed, including INS-5010 as a non-antibiotic treatment for Clostridium difficile-related colon infections. INS-3001, an inhibitor of cardiovascular calcification, is also in development for aortic valve stenosis. The companys efforts target unmet needs in infectious and cardiovascular conditions.
- Headquarters Zurich, Switzerland
- Stage Acquired
- SectorsHealthcare
- Website inositec.com
- Social LinkedIn
- Acquired by Vifor Pharma Benelux (Nov 2021)
- Total Equity Funding$1.42M (USD)
in 3 rounds
- Latest Funding Round$1.42M (USD), Seed
Oct 2016
- InvestorsZurcher Kantonalbank
& 3 more
- Acquired byVifor Pharma Benelux
(Nov 2021)
Funding Insights of Inositec
Inositec has successfully raised a total of $1.42M across 3 strategic funding rounds. The most recent funding activity was a Seed round of $1.42 million completed in October 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.42M
- Total Rounds 3
- Last Round Seed — $1.42M
- Investors Count 3
All 3 funding rounds of Inositec with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2016 | $1.42M | Seed | – | – | |
| Sep 2016 | $102,276 | Debt – Conventional | – | – | – |
| Jun 2015 | Seed | – | – |
4 investors in total: 4 institutional.
Investors in Inositec
Inositec has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Zurcher Kantonalbank, CSL Vifor and VIP Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage venture capital is invested in US and Europe. | vipartners.ch | Altendorf, Switzerland | ||
Commercial banking services are provided across Switzerland by Zurcher Kantonalbank. | 1870 | zkb.ch | Zurich, Switzerland | |
Swiss startups are supported through innovative programs by Venturelab. | 2004 | venturelab.ch | Switzerland | |
Plasma-derived therapies and vaccines are provided for rare diseases. | 1872 | viforpharma.com | Opfikon, Switzerland |
Investor details for Inositec
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Inositec
4 dated milestones of Inositec across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Inositec is founded.
- Funding First funding round.
- Funding Latest funding round, Seed, of $1.4M.
- Exit Acquired by Vifor Pharma Benelux.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Inositec
Complete news archive for Inositec
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Inositec
Inositec was founded in 2015.
Inositec is headquartered in Zurich, Switzerland.
Inositec is a funded company, having raised a total of $1.42M across 3 funding rounds to date.
Inositec was founded in 2015 in Zurich, Switzerland, with operations centered in the biotechnology sector. Therapeutics addressing soft tissue calcification disorders are developed, including INS-5010 as a non-antibiotic treatment for Clostridium difficile-related colon infections. INS-3001, an inhibitor of cardiovascular calcification, is also in development for aortic valve stenosis. The companys efforts target unmet needs in infectious and cardiovascular conditions.
Inositec has 4 investors. Key investors include Zurcher Kantonalbank, CSL Vifor, VIP Partners, and Venturelab.
Yes. Inositec was acquired by Vifor Pharma Benelux in November 2021.